BioSpecifics Technologies Corp. to Present at the NobleCon14 Conference

LYNBROOK, N.Y., Jan. 22, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming at NobleCon14 – Noble Capital Markets' Fourteenth Annual Investor Conference in Fort Lauderdale, Florida on Monday, January 29^th at 2:00pm E.T. 

A live webcast of the presentation can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or at http://noble.mediasite.com/mediasite/Play/16e8db9c20ff428085bebe039f77ccdf1d.  

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia. The XIAFLEX research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of XIAFLEX for uterine fibroids and is conducting a Phase 1 clinical trial. For more information, please visit www.biospecifics.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-noblecon14-conference-300584512.html

SOURCE BioSpecifics Technologies Corp.